Urigen Pharmaceuticals

About:

Urigen Pharmaceuticals designs and implements products for patients with urological ailments.

Top Investors: Platinum-Montaur Life Sciences

Description:

Urigen specializes in the design and implementation of innovative products for patients with urological ailments including, specifically, the development of innovative products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia and Over Active Bladder (OAB).

Total Funding Amount:

$9.11M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Wilmington, Delaware, United States

Founded Date:

1997-01-01

Contact Email:

info(AT)urigen.com

Founders:

C. Lowell Parsons

Number of Employees:

11-50

Last Funding Date:

2023-12-12

IPO Status:

Private

Industries: